Pharma sales in October shows 18.8 per cent growth

Highlights for October 2012

As per AIOCD-AWACS’ PharmaTrac, the Indian pharmaceutical market (IPM) is valued at Rs 6452 crores in October 2012. The Indian pharma market grew at a MAT (Moving Annual Total, sales for the 12-month period ending October) of 18.8 per cent for October 2012, compared to 16.7 per cent in the previous month. Among the top 10 companies, Mankind saw an impressive growth of 36.7 per cent and Zydus at 28.9 per cent. Three companies have crossed Rs 300 crores for the month of October 2012. Without bonus Sun Pharma is ranked second. Corona Remedies has registered highest growth of 113.8 per cent with current rank among corporates at 55 and heading towards the top 50.

From a therapy perspective the anti-infective market clocked a growth of 23.3 per cent whereas the respiratory segment has seen 20.1 per cent growth. The anti-diabetic market has grown at 22.6 per cent and cardiac at 16.9 per cent in chronic business.

Quarter on Quarter dynamics

Analysing quarter on quarter sales data, Q3 2012 (July-September) showed a slightly higher growth of 13.9 per cent over 13. 5 per cent in the same period last year.

About PharmaTrac

PharmaTrac is a the secondary sales data audit conducted by AIOCD Pharmasofttech AWACS, a pharmaceutical market research company formed by All Indian Origin Chemists & Distributors (AIOCD ) in a joint venture with Trikaal Mediinfotech.

AWACS in AIOCD AWACS stands for Advanced Working, Action & Correction System – reflecting the underlying philosophy behind AIOCD AWACS’ research tools to reduce time to information by 50 per cent or more and to significantly improve on accuracy of information. Accurate and faster information flows from the market will help clients grow topline and bottom-line.

Terminologies used

MAT – Moving Annual Total
MTH – Month
Val (Cr) – Value in Crs
MS% – Market Share in Percentage
GR% – Growth in percentage

For more information, visit http://www.aiocd.net